News | August 08, 2007

10 Percent of Patients Miss Out on Angioplasty

August 9, 2007 - Compared with their counterparts a decade ago, today's heart attack patients are receiving emergency angioplasty or clot-busting drugs to re-open clogged arteries at a far greater rate, but 10 percent of patients who could benefit from this life-saving treatment still do not receive it, according to a study published in The American Journal of Medicine by Yale and University of Michigan researchers.

The results also showed that the chance of missing out on lifesaving emergency treatment was highest among patients without typical symptoms like chest pain, patients who did not arrive at the hospital until six or more hours after the heart attack began, female patients, those over age 75 and non-whites.

The 10-year study was based on data from 238,291 heart attack patients between 1994 and 2003 who were listed in the National Registry of Myocardial Infarction. The patients had a particular kind of heart attack called ST-elevated myocardial infarction (STEMI). It is the most current and comprehensive look at the use of emergency reperfusion, a treatment that can restore blood flow to the heart muscle. To track the changes in emergency reperfusion therapy over time, the researchers divided the study data into three time periods: June 1994 through May 1997, June 1997 through May 2000, and June 2000 through May 2003.

"This study has good and bad news," said senior author Harlan M. Krumholz, M.D., the Harold H. Hines, Jr. Professor of Medicine at Yale School of Medicine. "We have definitely made progress in treating appropriate patients, but our findings indicate that we need to improve further to be sure that no patient who could benefit from treatment is missed."

"We may never be able to get to 100 percent, but 10 percent of eligible patients going untreated is still too many," said first author Brahmajee Nallamothu, M.D., assistant professor of cardiovascular medicine at the University of Michigan Medical School. "We hope our study highlights the opportunities to improve care and particularly some of the "at risk" subgroups still less likely to receive reperfusion therapy despite eligibility, so that we can focus our clinical efforts on them."

Hospitals around the nation, including Yale-New Haven and University of Michigan, are taking part in a national campaign to reduce "door-to-balloon" times-the time from when a STEMI patient enters hospital doors to the time blood flow is restored to the heart by opening a blockage with angioplasty.

The National Heart, Lung and Blood Institute of the National Institutes of Health funded the study. Genentech, Inc. provided researchers with access to the registry.

Other authors on the study included Martha E. Blaney, Susan M. Morris, Lori Parsons, Dave P. Miller, John G. Canto, M.D., and Hal V. Barron, M.D.,

Citation: The American Journal of Medicine, Vol. 120, No. 8, (August 2007)

For more information: www.yale.edu

Related Content

The Elixer Dynamx Coronary Bioadaptor Stent technology uses a bioresorbable polymer that dissolves after three months and disconnected joints between numerous stent segments, allowing it to articulate and share to the vessel and movement.

The Elixer Dynamx Coronary Bioadaptor Stent technology uses a bioresorbable polymer that dissolves after three months and disconnected joints between numerous stent segments, allowing it to articulate and shape to the vessel and its movement.

News | Stents | April 14, 2021
April, 14, 2021 – Elixir Medical recently announced the first patient was treated in the...
Comparison showing platelet adhesion to the surface of various coronary artery drug-eluting stents (DES) in a preclinical study that used aspirin only. Abbott said the Xience stent's fluoropolymer is significantly more anti-thrombotic than other DES.[2] 

Comparison showing platelet adhesion to the surface of various coronary artery drug-eluting stents (DES) in a preclinical study that used aspirin only. Abbott said the Xience stent's fluoropolymer is significantly more anti-thrombotic than other DES.[2] 

News | Stents | April 06, 2021
April 6, 2021 — Abbott today announced its Xience stent has received CE mark in Europe for shorter duration of dual a
The stent struts of the Biotronik Orsiro stent.
News | Stents | December 21, 2020
December 21, 2020 – A proposed ASTM International standard will answer the need for a standardized test method that a
One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT drug-eluting stent (DES), to the Xience or Promus Durable Polymer DES showed it was equivalent in clinical performance to the market-leading DES. The results were presented at the 2020 American Heart Association (AHA) Scientific Session. #AHA2020 #AHA20 #AHA

One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT drug-eluting stent (DES), to the Xience or Promus Durable Polymer DES showed it was equivalent in clinical performance to the market-leading DES. The results were presented at the 2020 American Heart Association (AHA) Scientific Session.

News | Stents | November 24, 2020
November 24, 2020 — One-year results off the...
Ori Ben-Yehuda, M.D., presenting the findings of the HOST-REDUCE-POLYTECH-ACS  study at TCT 2020 that showed durable polymer drug-eluting stents (DES) performed better than the bioresorbable polymer DES that were supposed to replace them with the promise of being safer and lowering overall cardiac event rates. #TCT2020 #TCTConnect

Ori Ben-Yehuda, M.D., presenting the findings of the HOST-REDUCE-POLYTECH-ACS study at TCT 2020 that showed durable polymer drug-eluting stents (DES) performed better than the bioresorbable polymer DES that were supposed to replace them with the promise of being safer and lowering overall cardiac event rates.

Feature | Stents | October 22, 2020 | Dave Fornell, Editor
October 17, 2020 – In a surprise to many, a randomized clinical trial found that drug-eluting stents (DES) with durab
For patients undergoing percutaneous coronary intervention (PCI), treatment with the CeloNova Biosciences nanotechnology polymer-coated Cobra PzF stent plus 14-day dual anti-platelet therapy (DAPT) did not reduce bleeding or establish non-inferior outcomes for thrombotic events compared with a drug-eluting stent (DES) and standard three or six-month DAPT therapy. #TCT #TCTconnect #TCT2020
News | Stents | October 22, 2020
October 22, 2020 – For patients undergoing percutaneous coronary intervention (PCI), treatment with the nanotechnolog
The FDA has cleared a new indication for the Medtronic Resolute Onyx Drug Eluting Stent, making it the first DES that only required one month of dual antiplatelet therapy (DAPT) in patients who are considered high risk for bleeding complications.

The FDA has cleared a new indication for the Medtronic Resolute Onyx Drug Eluting Stent, making it the first DES that only required one month of dual antiplatelet therapy (DAPT) in patients who are considered high risk for bleeding complications.

News | Stents | October 01, 2020
October 1, 2020 — Medtronic has received U.S.
News | Stents | July 24, 2020
July 24, 2020 — CeloNova BioSciences Inc.
Coronary and Peripheral Stent Market Expected to Double Through 2025
News | Stents | May 28, 2020
May 28, 2020 — The rising incidence of cardiovascular disease has prompted people to seek timely treatment to improve
The Boston Scientific Synergy stent uses a unique abluminal, bioresorbable drug-carrier polymer that dissolves after the vessel wall has healed months after the stent is implanted. Stent polymers have been implicated in cases of late-stent thrombosis, which required patients with DES to stay on dual antiplatelet therapy (DAPT). This study looked at using the device as a way to shorten DAPT duration. #SCAI2020

The Boston Scientific Synergy stent uses a unique abluminal, bioresorbable drug-carrier polymer that dissolves after the vessel wall has healed months after the stent is implanted. Stent polymers have been implicated in cases of late-stent thrombosis, which required patients with DES to stay on dual antiplatelet therapy (DAPT). This study looked at using the device as a way to shorten DAPT duration.

News | Stents | May 17, 2020
May 17, 2020 – A new study sought to reveal whether drug-eluting stents (DES) coated with bioabsorbable polymer (BP)